<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941992</url>
  </required_header>
  <id_info>
    <org_study_id>IOV-HN-1-2012 ROSAM</org_study_id>
    <secondary_id>2012-002046-20</secondary_id>
    <nct_id>NCT01941992</nct_id>
  </id_info>
  <brief_title>Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients</brief_title>
  <acronym>ROSAM</acronym>
  <official_title>Role of SAMITAL® in Prevention and Treatment of Oral Mucositis in Patients Treated With Chemo-radiation (CT/RT)for Head-and-neck Squamous Cell Carcinomas. A Double-blind, Phase 2 Placebo Controlled, Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indena S.p.A</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

        -  evaluate the activity of SAMITAL in reducing the incidence of severe mucositis in
           head-and-neck cancer patients undergoing chemo-radiotherapy.

        -  assess tolerability of SAMITAL and the impact on patients reported outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.</measure>
    <time_frame>Within 19 weeks after starting Radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0)</measure>
    <time_frame>Within 19 weeks after starting Radiotherapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&amp;N35)</measure>
    <time_frame>Within 19 weeks after starting Radiotherapy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Head-and-neck Squamous Cell Carcinoma</condition>
  <condition>Oral Mucositis.</condition>
  <arm_group>
    <arm_group_label>SAMITAL® sachets, oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAMITAL® sachets for oral suspension, 20 mL, four times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo sachets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sachets for oral suspension, 20 mL, four times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAMITAL®</intervention_name>
    <arm_group_label>SAMITAL® sachets, oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo sachets</intervention_name>
    <arm_group_label>Placebo sachets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinomas of the head-and-neck

          -  Eligible primary tumor sites: oral cavity, oropharynx, larynx, hypopharynx

          -  Stage III or IV disease without evidence of distant metastases

          -  Patients candidate to definitive concurrent chemo-radiotherapy or induction
             chemotherapy followed by chemo-radiotherapy

          -  Age ≥ 18 years

          -  Karnofsky Performance Status ≥70

          -  Life expectancy ≥6 months

          -  Able to swallow and retain oral medication

          -  Good state of dentition

          -  Patients must be available for treatment and follow-up

          -  Confirmation of adequate contraception use by the patient and/or partner

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous radiotherapy of the oral cavity, and/or oropharynx, larynx, hypopharynx

          -  Serious co-morbidities: uncontrolled heart disease, heart failure within 6 months
             prior to study participation, history of serious neurological and/or psychiatric
             abnormalities.

          -  Chronic administration of steroids or immunosuppressants

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucio Loreggian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiotherapy Department, Istituto Oncologico Veneto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiotherapy Department, Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>oral mucositis</keyword>
  <keyword>Chemo-radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

